This product is no longer in stock
Daklinza is used to treat hepatitis C virus (HCV) by activating the NS5A inhibitor. It is also used in the treatment the infection of HCV 1 and 3 concurrently with sofosbuvir and with or without ribavirin.
The most common side effects of Daklinza include somnolence, rash, headache, fatigue, diarrhea, nausea, anemia, insomnia, and dizziness.
Do not administer Daklinza with medications that induce the P-glycoprotein transporter (P-gp) and cytochrome P450 3A4 (CYP3A4) as they reduce the exposure to and efficacy of Daklinza. Medications that cause this include rifabutin, phenytoin, phenobarbital, carbamazepine, rifampicin, oxcarbazepine, rifapentine, St John’s wort, and systemic dexamethasone.
l.r.S Squibb Myers-Bristol, Italy
Also known as: Daclatasvir, Natdac, Daklahep, Dacihep, Daclacure, MyDecla, Dactovin, Hepcdac, Hepcvir, MyDacla, Daclavirocyrl, Dakvir, HepCfix